Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 42B22 | — |
a patient that received the hepatitis B vaccine for pediatric when it should have been for adult; a patient that received the hepatitis B vaccine for pediatric when it should have been for adult; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 33-year-old female patient who received HBV (Engerix B pediatric) (batch number 42B22, expiry date 07-MAR-2026) for prophylaxis. On an unknown date, the patient received Engerix B pediatric. On an unknown date, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: a patient that received the hepatitis B vaccine for pediatric when it should have been for adult) and underdose (Verbatim: a patient that received the hepatitis B vaccine for pediatric when it should have been for adult). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 20-MAR-2025 The nurse reported that a patient that received the hepatitis B vaccine for pediatric when it should have been for adult, which led to adult use of a child product and underdose. The reporter need to know if that should be repeated or know, what should be done about that. The first dose was administered a couple of weeks ago.